Efficacy

Vizimpro (Dacomitinib) Efficacy in Lung Cancer

Vizimpro (dacomitinib) is a kinase inhibitor specifically designed to target the epidermal growth factor receptor (EGFR), which is a common mutation found in non-small cell lung cancer (NSCLC). The efficacy of Vizimpro in the treatment of lung cancer was demonstrated in a pivotal phase III clinical trial known as ARCHER 1050. In this study, Vizimpro showed a significant improvement in progression-free survival (PFS) when compared to another EGFR inhibitor, gefitinib, in patients with previously untreated, EGFR mutation-positive NSCLC. Patients treated with Vizimpro experienced a median PFS of 14.7 months compared to 9.2 months in those treated with gefitinib, indicating a marked improvement in delaying disease progression.

Furthermore, Vizimpro also showed an improvement in overall survival (OS) in the same patient population. The median OS for patients treated with Vizimpro was 34.1 months, compared to 26.8 months for those receiving gefitinib. These findings suggest that Vizimpro can not only delay the progression of NSCLC but may also extend the lives of patients with EGFR-mutated NSCLC. However, it is important to note that Vizimpro is indicated for the first-line treatment of patients with NSCLC harboring EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Libtayo (Cemiplimab) Efficacy in Lung Cancer

Libtayo (cemiplimab) is a programmed death receptor-1 (PD-1) blocking antibody used in the treatment of certain types of NSCLC. Its efficacy in lung cancer was evaluated in a phase III trial involving patients with advanced NSCLC who had high PD-L1 expression and were either previously untreated or had disease progression on or after platinum-based chemotherapy. The results of this study showed that Libtayo significantly improved overall survival compared to chemotherapy. Specifically, the median OS was 22.1 months for patients treated with Libtayo, as opposed to 14.3 months for those on chemotherapy.

In addition to improved survival outcomes, Libtayo has also demonstrated a higher response rate and a longer duration of response compared to chemotherapy in the same patient population. These results have established Libtayo as a valuable treatment option for patients with advanced NSCLC with high PD-L1 expression, particularly for those who are either treatment-naive or have limited treatment options due to disease progression following chemotherapy. It is important for healthcare providers to assess PD-L1 expression levels in patients with NSCLC to determine the appropriateness of Libtayo as a treatment option.